Why the study?
Impairment of glycolytic metabolism is suggested to contribute to diabetic cardiomyopathy, prompting investigation into the roles of SIRT3 on cardiomyocyte glucose metabolism and cardiac function.
Does SIRT3 overexpression improve cardiac function and metabolism in models of diabetic cardiomyopathy?
Does SIRT3 overexpression improve cardiac function and metabolism in models of diabetic cardiomyopathy?
SIRT3 overexpression attenuates diabetic cardiomyopathy by regulating p53 acetylation and TIGAR expression, suggesting a potential therapeutic target for abnormal energy metabolism in diabetes.
No takes yet. Share an insight, caveat, or question.
SIRT3 modulation in diabetic cardiomyopathy remains experimental; leaves open its mechanistic and therapeutic relevance pending in vivo and clinical validation.
Li et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: